Skip to search formSkip to main contentSkip to account menu

ABT-869

Known as: ABT 869, ABT869, multitargeted receptor tyrosine kinase inhibitor ABT-869 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

linifanib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
2013
2013
Exposure-response (safety) analysis to identify linifanib dose for a Phase III study in patients with hepatocellular carcinoma.
2012
2012
3-Phenyl-1H-5-pyrazolylamine-based derivatives as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
2012
2012
FDG-PET as a pharmacodynamic biomarker for early assessment of treatment response to linifanib (ABT-869) in a non-small cell lung cancer xenograft model
Linifanib (ABT-869) is a multitargeted receptor tyrosine kinase inhibitor. This work aims to evaluate F-fluorodeoxyglucose… 
2011
2011
Discovery and evaluation of 3-phenyl-1H-5-pyrazolylamine-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
2009
2009
ETA Receptor Blockade With Atrasentan Prevents Hypertension With the Multitargeted Tyrosine Kinase Inhibitor ABT-869 in Telemetry-instrumented Rats
ABT-869 is a novel multitargeted inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptor… 
2009
2009
Phase II trial of ABT-869 in advanced renal cell cancer (RCC) after sunitinib failure: Efficacy and safety results.
5036 Background: ABT-869 is a novel, orally active and potent inhibitor of all VEGF and PDGF receptor tyrosine kinases. Results… 
Highly Cited
2008
Highly Cited
2008
Simultaneous determination of a hydrophobic drug candidate and its metabolite in human plasma with salting-out assisted liquid/liquid extraction using a mass spectrometry friendly salt.
2006
2006
A high-throughput, fully automated liquid/liquid extraction liquid chromatography/mass spectrometry method for the quantitation of a new investigational drug ABT-869 and its metabolite A-849529 in…
ABT-869 is a novel ATP-competitive inhibitor for all the vascular endothelial growth factor (VEGF) and platelet-derived growth… 
2005
2005
Preclinical activity of ABT-869, a novel receptor tyrosine kinase inhibitor, alone or in combination with paclitaxel
3175 Background: ABT-869, a multi-targeted receptor tyrosine kinase inhibitor, has been shown to inhibit of all members of the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)